- Home
- ZD vs AKRO Comparison
ZD vs AKRO Comparison
Compare ZD & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZD
- AKRO
- Stock Information
- Founded
- ZD 1995
- AKRO 2017
- Country
- ZD United States
- AKRO United States
- Employees
- ZD N/A
- AKRO N/A
- Industry
- ZD Advertising
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ZD Consumer Discretionary
- AKRO Health Care
- Exchange
- ZD Nasdaq
- AKRO Nasdaq
- Market Cap
- ZD 1.3B
- AKRO 3.9B
- IPO Year
- ZD 1999
- AKRO 2019
- Fundamental
- Price
- ZD $33.11
- AKRO $52.40
- Analyst Decision
- ZD Hold
- AKRO Strong Buy
- Analyst Count
- ZD 6
- AKRO 6
- Target Price
- ZD $49.67
- AKRO $82.50
- AVG Volume (30 Days)
- ZD 612.6K
- AKRO 1.7M
- Earning Date
- ZD 08-06-2025
- AKRO 08-08-2025
- Dividend Yield
- ZD N/A
- AKRO N/A
- EPS Growth
- ZD 36.58
- AKRO N/A
- EPS
- ZD 1.76
- AKRO N/A
- Revenue
- ZD $1,415,839,000.00
- AKRO N/A
- Revenue This Year
- ZD $7.37
- AKRO N/A
- Revenue Next Year
- ZD $3.65
- AKRO N/A
- P/E Ratio
- ZD $18.24
- AKRO N/A
- Revenue Growth
- ZD 3.24
- AKRO N/A
- 52 Week Low
- ZD $29.15
- AKRO $21.34
- 52 Week High
- ZD $60.62
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ZD 56.71
- AKRO 52.50
- Support Level
- ZD $31.70
- AKRO $50.13
- Resistance Level
- ZD $33.77
- AKRO $52.73
- Average True Range (ATR)
- ZD 1.34
- AKRO 2.09
- MACD
- ZD 0.22
- AKRO -0.76
- Stochastic Oscillator
- ZD 82.95
- AKRO 34.00
About ZD Ziff Davis Inc.
Ziff Davis Inc is a focused digital media and internet company whose portfolio includes brands in technology, entertainment, shopping, health, cybersecurity, and martech. It has two reportable segments: Digital Media and Cybersecurity and Martech. The company's brands include Mashable, Ookla, Offers.com, IGN, and VPN among others. The majority of revenue is generated from Digital Media.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.